newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

  • Cogent Biosciences announced three presentations featuring bezuclastinib at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL, December 6-9, 2025.
  • Two oral presentations will highlight SUMMIT trial data for bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM), including efficacy & safety results presented by Dr. Lindsay Rein on December 6 & pathobiology changes presented by Dr. Tracy George on December 8.
  • A poster presentation will describe the relationship between KIT inhibition by bezuclastinib & disease burden in mouse models of systemic mastocytosis on December 8.
  • Cogent will also present preclinical data on a novel JAK2 V617F mutant-selective inhibitor, which is on-track for an IND submission in 2026.
  • CEO Andrew Robbins stated that bezuclastinib data supports its potential to become the preferred standard of care for NonAdvSM patients.
  • The JAK2 V617F inhibitor is described as wild-type-sparing with best-in-class potential based on its potency & selectivity.
  • Full abstracts for all presentations will be available online via the ASH Annual Meeting website.
  • Cogent Biosciences is developing a portfolio of targeted therapies for genetically defined diseases, including bezuclastinib for KIT-driven systemic mastocytosis & GIST.